Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oncotelic Therapeutics Inc
(OP:
OTLC
)
0.0207
+0.0002 (+0.98%)
Streaming Delayed Price
Updated: 2:38 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,378,706
Open
0.0215
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0205
Today's Range
0.0197 - 0.0220
52wk Range
0.0197 - 0.0500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
May 29, 2024
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Via
News Direct
Exposures
Product Safety
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
April 10, 2024
With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
Via
News Direct
Topics
Death
Exposures
Death
Performance
YTD
-54.00%
-54.00%
1 Month
-26.07%
-26.07%
3 Month
-45.53%
-45.53%
6 Month
-45.09%
-45.09%
1 Year
-11.16%
-11.16%
More News
Read More
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
February 21, 2024
Via
News Direct
Exposures
COVID-19
Oncotelic Therapeutics’ (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 11, 2023
Via
News Direct
Exposures
COVID-19
Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
October 10, 2023
Via
Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
September 27, 2023
Via
News Direct
Exposures
COVID-19
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
September 25, 2023
Via
Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
September 13, 2023
Via
News Direct
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
September 11, 2023
Via
Benzinga
The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge
September 11, 2023
Via
Benzinga
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
November 30, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
November 16, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
November 08, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
October 12, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Announces Formation of Animal Health Division
October 06, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
September 28, 2022
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022
Via
Talk Markets
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
December 14, 2021
Via
News Direct
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
November 23, 2021
Via
News Direct
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
COVID-19
Legal
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.